

ASX ANNOUNCEMENT

CELLMID SHARE PURCHASE PLAN COMPLETED

SYDNEY, **Wednesday**, **6 November 2019**: **Cellmid Limited (ASX: CDY)** advises that the Share Purchase Plan ("**SPP**") announced on 14 October 2019 with an offer price of \$0.20 has now closed, substantially over the \$0.5 million originally targeted by the Board.

The Company received applications to the value of \$1.044m for the issuing of 5,220,000 shares. In the spirit of the SPP concept, the Board has approved the issue and there will be no scale back of applications. The SPP was offered at the same price as the share placement to sophisticated and institutional investors for \$1.5 million, also announced on 14 October 2019. The Company expects the shares under the SPP to be allotted on or around 8 November 2019.

The \$2.5 million raised under the share placement and the SPP will be used to drive growth in the consumer health business globally, including the recently signed partnerships with Douglas in Germany, openshop in Australia and Habesul in China (ASX announcements 1 October 2019 and 14 October 2019).

Cellmid CEO, Maria Halasz said, "We thank our shareholders and new investors for their support in this capital raising. The additional funding will allow us to fast track our growth with our partners and invest into our e-commerce capabilities to fulfill the increasing demand for our products locally and overseas."

END

Company	Investment Enquiries
Maria Halasz, CEO	Gennadi Koutchin
Cellmid Limited	XEC Partners
T+612 9221 6830	T 1300 932 037
info@cellmid.com.au	gkoutchin@xecpartners.com.au

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Lyramid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) globally.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.